Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Didanosine

Catalog No: tcsc2229

Available Sizes

Size: 10mg

Size: 50mg

Specifications

CAS No:
69655-05-6

Formula:
$C_{10}H_{12}N_4O_3$

Pathway:
Anti-infection;Anti-infection

Target:
Reverse Transcriptase;HIV

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 65 mg/mL (275.16 mM)

Alternative Names:
2',3'-Dideoxyinosine;ddI

Observed Molecular Weight:
236.23

Product Description

Didanosine(Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μM.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Target: NRTIs; HIV

Didanosine is a dideoxynucleoside compound in which the 3\'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Didanosine demonstrated linear pharmacokinetic behavior over the dose ranges of 0.4 to 16.5 mg/kg intravenously and 0.8 to 10.2 mg/kg orally. Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex. Bioavailability of didanosine from the citrate-phosphate-buffered solution, the formulation currently used in phase II and expanded access studies, was comparable to the formulation used in the phase I trials [1]. ddI might be responsible for fulminant hepatitis in all three AIDS patients. This toxic effect may be added to the list of potential adverse events occurring during ddI therapy [2].